Clinical data | |
---|---|
Trade names | Micardis |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601249 |
Pregnancy category |
|
Routes of administration |
Oral |
ATC code | C09CA07 (WHO) |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 42–100% |
Protein binding | >99.5% |
Metabolism | Minimal hepatic (glucuronidation) |
Biological half-life | 24 hours |
Excretion | Faecal 97% |
Identifiers | |
|
|
CAS Number | 144701-48-4 |
PubChem (CID) | 65999 |
IUPHAR/BPS | 592 |
DrugBank | DB00966 |
ChemSpider | 59391 |
UNII | U5SYW473RQ |
KEGG | D00627 |
ChEBI | CHEBI:9434 |
ChEMBL | CHEMBL1017 |
ECHA InfoCard | 100.149.347 |
Chemical and physical data | |
Formula | C33H30N4O2 |
Molar mass | 514.617 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
Telmisartan (INN) /tɛlmɪˈsɑːrtən/ is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. It was discovered by Boehringer Ingelheim and launched in 1999 as Micardis.
In January 2014, Actavis as generic version of Micardis got appoval from FDA.
Telmisartan is indicated in the treatment of essential hypertension.
Telmisartan is contraindicated during pregnancy. Like other drugs affecting the renin-angiotensin system (RAS), telmisartan can cause birth defects, stillbirths, and neonatal deaths. It is not known whether the drug passes into the breast milk. Also it is contraindicated in bilateral renal artery stenosis in which it can cause renal failure.
Side effects are similar to other angiotensin II receptor antagonists and include tachycardia and bradycardia (fast or slow heartbeat), hypotension (low blood pressure), edema (swelling of arms, legs, lips, tongue, or throat, the latter leading to breathing problems), and allergic reactions.